Orlistat

• Description:

  Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1]. Anti-atherosclerotic effect[2].

• Product Name Alternative:

  Tetrahydrolipstatin; Ro-18-0647

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H412

• Target:

  Apoptosis; Fatty Acid Synthase (FASN)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Metabolic Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/orlistat.html

• Concentration:

  10mM

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles:

  O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1

• Molecular Formula:

  C29H53NO5

• Molecular Weight:

  495.73

• Precautions:

  H302, H412

• References & Citations:

  [1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47 (2) :764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel) . 2021 Feb 6;10 (2) :251.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [96829-58-2]